Original Article

Impact of Benzodiazepine Use on Length of Stay and 30-Day ED Visits among Hospitalized Hematopoietic Stem Cell Transplant Recipients

Authors: Shehzad K. Niazi, MD, Madiha Iqbal, MD, Aaron C. Spaulding, PhD, Chanel Wood, MD, Rami Manochakian, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Emily Brennan, MPH, Mohamed A. Kharfan Dabaja, MD, Taimur Sher, MD

Abstract

Objectives: This study assesses the impact of benzodiazepine (BNZ) use on length of stay (LOS) and 30-day emergency department (ED) visits after hematopoietic stem cell transplant (HSCT).

Methods: Adult patients (18 years and older) who underwent an allogeneic or an autologous HSCT from 2015 to 2018 at the study site were included. Five multivariable models were used for both allogeneic and autologous HSCT: BNZ-naïve status, diazepam equivalent daily dosage (DEDD; 0 vs any), DEDD (excluding 0), ED visits, and LOS.

Results: BNZ-naïve autologous HSCT recipients were less likely to use any BNZs in the hospital (odds ratio [OR] 0.07, P < 0.001). If prescribed BNZs, then they used a lesser amount (incidence rate ratio 0.39, P < 0.001). BNZ-naïve autologous HSCT recipients were less likely to experience a 30-day ED visit (OR 0.17, P = 0.009). BNZ-naïve allogeneic HSCT recipients were also less likely to use any BNZ than previous users (OR 0.11, P = 0.014). Patient characteristics influenced BNZ naïvety, DEDD usage, LOS for autologous patients, and BNZ naïvety and DEDD for allogeneic patients.

Conclusions: BNZ use resulted in increased 30-day ED visits after autologous HSCT. BNZ-naïve recipients were less likely to use BNZs during hospital stays; if they required BNZs, then it was in lower dosages.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863–1869.
 
2. Center for International Blood and Marrow Transplant Research. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2019. https://www.cibmtr.org. October 20, 2020.
 
3. Bentley TS. 2014 U.S. organ and tissue transplant cost estimates and discussion. Milliman’s triennial summary report. https://us.milliman.com/en/insight/2014-usorgan-and-tissue-transplant-cost-estimates-and-discussion. Accessed October 15, 2020.
 
4. Driscoll D, Farnia S, Kefalas P, et al. Concise review: the high cost of high tech medicine: planning ahead for market access. Stem Cells Transl Med 2017;6:1723–1729.
 
5. Gajewski JL, Foote M, Tietjen J, et al. Blood and marrow transplantation compensation: perspective in payer and provider relations. Biol Blood Marrow Transplant 2004;10:427–432.
 
6. American College of Emergency Physicians. Emergency medicine and payment reform. https://www.acep.org/administration/reimbursement/emergency-medicine-and-payment-reform/. Published August 2014. Accessed April 15, 2020.
 
7. Brennan JJ, Chan TC, Killeen JP, et al. Inpatient readmissions and emergency department visits within 30 days of a hospital admission. West J Emerg Med 2015;16:1025–1029.
 
8. Berger E. A $9,000 bill to diagnose shingles? Doctor's ED visit highlights cost of care issues. Ann Emerg Med 2010;55:A15–A17.
 
9. Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits 2017;10: 366–374.
 
10. Seo HJ, Baek YG, Cho BS, et al. Anxiety and depression of the patients with hematological malignancies during hospitalization for hematopoietic stem cell transplantation. Psychiatry Investig 2019;16:751–758.
 
11. Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv 2019;70:97–106.
 
12. Shinfuku M, Kishimoto T, Uchida H, et al. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol 2019;34:211–221.
 
13. Nakao M, Sato M, Nomura K, et al. Benzodiazepine prescription and length of hospital stay at a Japanese university hospital. Biopsychosoc Med 2009;3:10.
 
14. Kaufmann CN, Spira AP, Alexander GC, et al. Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists. Am J Emerg Med 2017;35:1414–1419.
 
15. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Austr Prescriber 2015;38:152.
 
16. Thekkumpurath P, Walker J, Butcher I, et al. Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire. Cancer 2011;117:218–227.
 
17. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166: 1092–1097.
 
18. Baker LC, Baker LS. Excess cost of emergency department visits for nonurgent care. Health Aff (Millwood) 1994;13:162–171.
 
19. Fitch KV, Pelizzari PM, Pyenson BS. Cost Drivers of Cancer Care: A Retrospective Analysis of Medicare and Commercially Insured Population Claim Data 2004-2014. https://www.milliman.com/en/insight/cost-drivers-of-cancer-care-a-retrospective-analysis-of-medicare-and-commercially-insured. Published April 2016. Accessed September 19, 2022.
 
20. Niazi S, Frank RD, Sharma M, et al. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv 2018; 2:1120–1128.
 
21. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72:136–142.
 
22. Jessell L, Stanhope V, Manuel JI, et al. Factors associated with benzodiazepine prescribing in community mental health settings. J Subst Abuse Treat 2020; 109:56–60.
 
23. Wells K, Klap R, Koike A, et al. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am J Psychiatry 2001; 158:2027–2032.
 
24. Stockdale SE, Lagomasino IT, Siddique J, et al. Racial and ethnic disparities in detection and treatment of depression and anxiety among psychiatric and primary health care visits, 1995-2005. Med Care 2008;46:668–677.
 
25. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care 2003;41:479–489.
 
26. Dwight-Johnson M, Sherbourne CD, Liao D, et al. Treatment preferences among depressed primary care patients. J Gen Intern Med 2000;15: 527–534.
 
27. Michelini S, Cassano GB, Frare F, et al. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996;29:127–134.
 
28. Centers for Medicare & Medicaid Services Innovation Center. Oncology Care Model overview. https://innovation.cms.gov/files/slides/ocm-overview-slides.pdf. Published February 2021. Accessed September 19, 2022.